| The role of bisphosphonates in the adjuvant setting for breast cancer. | |
| | |
MedLine Citation:
|
PMID: 20568587 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Bone health is a critical issue in the management of women with breast cancer. Many women who develop breast cancer are postmenopausal, which already predisposes them to osteoporosis. Systemic treatments for breast cancer, including chemotherapy and endocrine therapy, decrease circulating levels of estrogen in both pre- and postmenopausal women, further accelerating the natural process of bone loss. The primary concern in breast cancer patients is that this accelerated bone loss, known as cancer treatment-induced bone loss (CTIBL), will lead to an increase in fractures, chronic pain, and loss of mobility. Bisphosphonates are highly effective at slowing the rate of bone loss in postmenopausal women with osteoporosis and at preventing skeletal-related events in women with metastatic breast cancer. Many studies are now focusing on the role of bisphosphonates in preventing CTIBL in the adjuvant setting. Both oral and intravenous bisphosphonates have shown promising activity in preventing CTIBL in patients receiving chemotherapy or hormonal therapy. In addition, emerging data indicate that the use of bisphosphonates in the adjuvant setting may prevent disease recurrence and prolong survival. Data from a number of ongoing trials will further elucidate the role of bisphosphonates in the adjuvant setting over the next few years. |
| | |
Authors:
|
Jennifer G Reeder; Adam M Brufsky |
Related Documents
:
|
11684727 - Mantle cell lymphoma presenting as a breast mass. 8467247 - Procollagen type i carboxy-terminal propeptide as a marker of osteoblastic bone metasta... 6494827 - Bone scintigraphy and serum phosphatases in the detection and follow-up of bone metasta... 18850577 - Mitochondrial dna mutation stimulates prostate cancer growth in bone stromal environment. 17441897 - A case of pulmonary type of ovarian small cell carcinoma. 18776787 - Role of sonography after total thyroidectomy for thyroid cancer. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Oncology (Williston Park, N.Y.) Volume: 24 ISSN: 0890-9091 ISO Abbreviation: Oncology (Williston Park, N.Y.) Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-06-23 Completed Date: 2010-07-08 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8712059 Medline TA: Oncology (Williston Park) Country: United States |
Other Details:
|
Languages: eng Pagination: 462-7, 475 Citation Subset: IM |
Affiliation:
|
Division of Hematology/Oncology, Magee-Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15232, USA. reederj2@upmc.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
adverse effects Aromatase Inhibitors / adverse effects Bone Density Conservation Agents / therapeutic use* Bone Remodeling Breast Neoplasms / drug therapy* Clinical Trials as Topic Diphosphonates / therapeutic use* Female Humans Osteoporosis / etiology, prevention & control* |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Aromatase Inhibitors; 0/Bone Density Conservation Agents; 0/Diphosphonates |
| Comments/Corrections | |
Comment In:
|
Oncology (Williston Park). 2010 May;24(6):475, 478, 480
[PMID:
20568588
]
Oncology (Williston Park). 2010 May;24(6):480, 485 [PMID: 20568589 ] |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The impact of the National Practitioner Data Bank on licensing actions by state medical licensing bo...
Next Document: Diagnosis and management of mycosis fungoides.